The Houston Astros beat the New York Yankees in the American League Championship Series, settling a Twitter bet between MD Anderson and Memorial Sloan Kettering’s presidents Peter W.T. Pisters and Selwyn M. Vickers.Â
The James P. Allison Institute at MD Anderson Cancer Center established an internal advisory council to provide scientific input and to align the work of the institute with the broader MD Anderson research enterprise.
MD Anderson Cancer Center President Peter W.T. Pisters challenged Selwyn M. Vickers, president and CEO of Memorial Sloan Kettering Cancer Center, to a friendly Twitter bet.Â
MD Anderson Cancer Center and World Health Organization formed an agreement to establish a new international collaboration concentrated on reducing the global burden of women’s cancers. The agreement builds on years of collaboration between the two institutions to further promote their shared efforts in advancing global cancer initiatives in women’s cancers, including breast and cervical cancers.
MD Anderson Cancer Center and ARTIDIS AG have formed a strategic alliance to investigate ARTIDIS technology as a novel treatment-optimization tool for patients with solid tumors in several distinct indications.
Through extensive single-cell analysis, researchers at MD Anderson Cancer Center have created a spatial map of tumor-infiltrating B cells and plasma cells in early-stage lung cancers, highlighting previously unappreciated roles these immune cells play in tumor development and treatment outcomes.
In an international, multicenter phase II clinical trial led by MD Anderson Cancer Center, 63.3% of patients with stage II–IV cutaneous squamous cell carcinoma saw their tumors nearly or completely disappear when treated with immunotherapy before surgery.Â
Phase I/II ARROW trial results show that pralsetinib, a highly selective RET inhibitor, was well-tolerated and demonstrated robust, durable responses in patients with RET fusion-positive cancers regardless of tumor type.
MD Anderson Cancer Center announced a strategic collaboration to accelerate the development of investigational treatments, including oncolytic viruses and immunotherapies.Â
The James P. Allison Institute at MD Anderson Cancer Center established an 11-person scientific advisory board to provide strategic guidance and evaluation of its research portfolio and programs.Â
